Title:
GENETICALLY MODIFIED CELL AND PRODUCING METHOD THEREFOR
Document Type and Number:
WIPO Patent Application WO/2019/177151
Kind Code:
A1
Abstract:
Provided is a production of a cell expressing a variant chimeric antigen receptor (CAR) having excellent target cytotoxicity. Provided is a genetically modified cell into which a polynucleotide is introduced, the polynucleotide encoding a chimeric antigen receptor (CAR) protein having: a target binding domain which specifically binds to a human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor; a transmembrane domain; and an intracellular signaling domain, wherein the target binding domain is a variant in which a glutamic acid of the 21st in the amino acid sequence represented by SEQ ID NO: 1 is substituted with another amino acid.
Inventors:
NAKAZAWA YOZO (JP)
HASEGAWA AIKO (JP)
TANAKA MIYUKI (JP)
NAKANO SHIGERU (JP)
NARIMATSU SHOGO (JP)
HASEGAWA AIKO (JP)
TANAKA MIYUKI (JP)
NAKANO SHIGERU (JP)
NARIMATSU SHOGO (JP)
Application Number:
PCT/JP2019/010854
Publication Date:
September 19, 2019
Filing Date:
March 15, 2019
Export Citation:
Assignee:
KISSEI PHARMACEUTICAL (JP)
UNIV SHINSHU (JP)
UNIV SHINSHU (JP)
International Classes:
C12N15/62; A61K35/12; A61P35/02; C12N5/10; C12N15/12; C12N15/13; C12N15/27; C12N15/85
Domestic Patent References:
| WO2015066262A1 | 2015-05-07 | |||
| WO2018052142A1 | 2018-03-22 |
Foreign References:
| JP2018050266A | 2018-03-29 |
Other References:
NAKAZAWA Y. ET AL.: "Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD 116 on CD 34+ cells of juvenile myelomonocytic leukemia.", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 9, 27 September 2016 (2016-09-27), pages 27-1 - 27-11, XP002758093
IVERSEN P. 0. ET AL.: "Apoptosis of hemopoietic cells by the human granulocyte-macrophage colony-stimulating factor mutant E21R.", PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 2785 - 2789, XP002934530, DOI: 10.1073/pnas.93.7.2785
ALTMANN S. W. ET AL.: "Rational Design of a Mouse Granulocyte Macrophage-Colony-stimulating Factor Receptor Antagonist.", J. BIOL. CHEM., vol. 270, no. 5, 1995, pages 2233 - 2240, XP055637600
JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 9, 2016, pages 27
THE 22ND ANNUAL MEETING JSGCT2016: JAPAN SOCIETY OF GENE AND CELL THERAPY PROGRAM AND ABSTRACTS, 13 July 2016 (2016-07-13)
JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 10, 2017, pages 151
BLOOD, vol. 122, no. 18, 2013, pages 3138 - 3148
BLOOD CANCER JOURNAL, vol. 6, 2016, pages e458
"Uniprot", Database accession no. P 10747
"NCBI", Database accession no. NM 000734.3
ONCOIMMUNOLOGY, vol. 5, no. 12, 2016, pages e1253656
YANG XU ET AL., BLOOD, vol. 123, 2014, pages 3750 - 3759
HUANG XGUO H ET AL., MOL THER, vol. 16, 2008, pages 580 - 9
SINGH HMANURI PR ET AL., CANCER RES, vol. 68, 2008, pages 2961 - 71
DENIGER DCYU J ET AL., PLOS ONE, vol. 10, 2015, pages e0128151
SINGH HMOYES JS ET AL., CANCER GENE THER, vol. 22, 2015, pages 95 - 100
HOU XDU Y ET AL., CANCER BIOL THER, vol. 16, 2015, pages 8 - 16
SINGH HHULS H ET AL., IMMUNOL REV, vol. 257, 2014, pages 181 - 90
NAKAZAWA YSAHA S ET AL., J IMMUNOTHER, vol. 36, 2013, pages 112 - 10
GALVAN DLNAKAZAWA Y ET AL., J IMMUNOTHER, vol. 32, 2009, pages 837 - 44
HUYE LENAKAZAWA Y ET AL., MOL THER, vol. 19, no. 12, 2011, pages 2239 - 2248
SAHA SNAKAZAWA Y ET AL., J VIS EXP, vol. 69, 2012, pages e4235
SAITO SNAKAZAWA Y ET AL., CYTOTHERAPY, vol. 16, 2014, pages 1257 - 69
ZOLA H. ET AL., IMMUNOL CELL BIOL, vol. 69, no. Pt6, 1991, pages 411 - 412
SAVOLDO ET AL., J CLIN INVEST, vol. 121, no. 5, 2011, pages 1822 - 1826
MORITA ET AL., MOLECULAR THERAPY: METHODS & CLINICAL DEVELOPMENT, vol. 8, March 2018 (2018-03-01)
See also references of EP 3766977A4
IVERSEN P. 0. ET AL.: "Apoptosis of hemopoietic cells by the human granulocyte-macrophage colony-stimulating factor mutant E21R.", PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 2785 - 2789, XP002934530, DOI: 10.1073/pnas.93.7.2785
ALTMANN S. W. ET AL.: "Rational Design of a Mouse Granulocyte Macrophage-Colony-stimulating Factor Receptor Antagonist.", J. BIOL. CHEM., vol. 270, no. 5, 1995, pages 2233 - 2240, XP055637600
JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 9, 2016, pages 27
THE 22ND ANNUAL MEETING JSGCT2016: JAPAN SOCIETY OF GENE AND CELL THERAPY PROGRAM AND ABSTRACTS, 13 July 2016 (2016-07-13)
JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 10, 2017, pages 151
BLOOD, vol. 122, no. 18, 2013, pages 3138 - 3148
BLOOD CANCER JOURNAL, vol. 6, 2016, pages e458
"Uniprot", Database accession no. P 10747
"NCBI", Database accession no. NM 000734.3
ONCOIMMUNOLOGY, vol. 5, no. 12, 2016, pages e1253656
YANG XU ET AL., BLOOD, vol. 123, 2014, pages 3750 - 3759
HUANG XGUO H ET AL., MOL THER, vol. 16, 2008, pages 580 - 9
SINGH HMANURI PR ET AL., CANCER RES, vol. 68, 2008, pages 2961 - 71
DENIGER DCYU J ET AL., PLOS ONE, vol. 10, 2015, pages e0128151
SINGH HMOYES JS ET AL., CANCER GENE THER, vol. 22, 2015, pages 95 - 100
HOU XDU Y ET AL., CANCER BIOL THER, vol. 16, 2015, pages 8 - 16
SINGH HHULS H ET AL., IMMUNOL REV, vol. 257, 2014, pages 181 - 90
NAKAZAWA YSAHA S ET AL., J IMMUNOTHER, vol. 36, 2013, pages 112 - 10
GALVAN DLNAKAZAWA Y ET AL., J IMMUNOTHER, vol. 32, 2009, pages 837 - 44
HUYE LENAKAZAWA Y ET AL., MOL THER, vol. 19, no. 12, 2011, pages 2239 - 2248
SAHA SNAKAZAWA Y ET AL., J VIS EXP, vol. 69, 2012, pages e4235
SAITO SNAKAZAWA Y ET AL., CYTOTHERAPY, vol. 16, 2014, pages 1257 - 69
ZOLA H. ET AL., IMMUNOL CELL BIOL, vol. 69, no. Pt6, 1991, pages 411 - 412
SAVOLDO ET AL., J CLIN INVEST, vol. 121, no. 5, 2011, pages 1822 - 1826
MORITA ET AL., MOLECULAR THERAPY: METHODS & CLINICAL DEVELOPMENT, vol. 8, March 2018 (2018-03-01)
See also references of EP 3766977A4
Attorney, Agent or Firm:
HIRAKI & ASSOCIATES (JP)
Download PDF:
Previous Patent: ELECTROSTATIC SOUND WAVE GENERATION DEVICE AND ELECTROSTATIC SPEAKER
Next Patent: EFFECTIVE CLUSTERING OF IMMUNOLOGICAL ENTITIES
Next Patent: EFFECTIVE CLUSTERING OF IMMUNOLOGICAL ENTITIES